메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Alzheimer's Association Statement on Oral Semaglutide Phas…

- Results Underscore Need for Continued Research and Diverse Treatment Pipeline CHICAGO, Nov. 24, 2025 -- The Alzheimer's Association is disappointed that the evoke and evoke+ clinical trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression. The studies tested an oral semaglutide pill for the treatment of early-stage symptomatic Alzheimer's disease. "While these results are not what we had hoped for, they will contribute to our understanding of this devastating and fatal disease," said Joanne Pike, DrPH, Alzheimer's A
- 김갑성 기자
- 2025-11-24 23:19
ToolGen and GenEditBio Enter Strategic Cross-License Agre…

Integrates ToolGen's best-in-class CRISPR-Cas9 platform with GenEditBio's industry-leading lipid nanoparticle (LNP) delivery technology Pursues a "once-and-done" treatment paradigm for diseases with high unmet medical needs SEOUL, South Korea, Nov. 24, 2025 -- ToolGen Inc. (KOSDAQ: 199800), a leading genome editing company based in Korea, announced today that it has entered into a strategic cross-license agreement with GenEditBio Limited ("GenEditBio"), a Hong Kong-headquartered clinical-stage biotechnology company specializing in novel deliveries, in
- 김갑성 기자
- 2025-11-24 22:00
Kelun-Biotech Announces Phase III Trial of Sac-TMT in Com…

CHENGDU, China, Nov. 24, 2025 -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that the Independent Data Monitoring Committee (IDMC) concluded that the Phase III clinical study (OptiTROP-Lung05) of the company's TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870), in combination with MSD's anti-PD-1 therapy KEYTRUDA®[1] (pembrolizumab), as a first-line treatment for PD-L1-positive advanced non-small cell lung cancer (NSCLC), has demonstrated a statistically significant and clinically meaningful improvemen
- 김갑성 기자
- 2025-11-24 20:00
Triple the Probiotics, Triple the Relief: Life-Space Launche…

Engineered by Australia's leading probiotics expert, this high CFU probiotic delivers the ultimate gut defense, helping to reduce gut transit time by up to 18 hours. SINGAPORE, Nov. 24, 2025 -- Life-Space, Australia's No.1 probiotic brand, proudly unveils Triple Strength Probiotics, a flash charged probiotic designed to deliver intensive gut health support for those with more demanding digestive needs. With 15 premium strains and three times the beneficial bacteria of regular Broad Spectrum Probiotic formulations, this high-strength solution delivering 96 billion CFU's per capsule repr
- 김갑성 기자
- 2025-11-24 18:29
HoneyNaps Accelerates Clinical Trial Pipelines with FDA-Clea…

[ 메디채널 김갑성 기자 ] Enhancing Clinical Efficiency with AI Sleep Analysis: Cutting Both Cost and Time Joint Clinical Studies with CROs: SOMNUM™ AI Sleep Scoring Drives Higher Efficiency FDA-cleared AI solution shortens clinical trial timelines while ensuring data reliability Expanded global partnerships with CROs enable a large-scale clinical data analysis platform BOSTON, Nov. 24, 2025 -- HoneyNaps, an AI-driven sleep-medicine technology company, announced that its AI-based sleep disorder diagnostic support software, SOMNUM™, which recently received clearance from the U.S. Food a
- 김갑성 기자
- 2025-11-24 17:24
Beyfortus® (nirsevimab) now available in Malaysia to protect…

[ 메디채널 김갑성 기자 ] Beyfortus® (nirsevimab) is an available option designed to protect all infants – whether born full-term or pre-term, healthy or with underlying conditions – against respiratory syncytial virus (RSV), with proven high and sustained efficacy, a favourable safety profile, and real-world public health impact.[1] Administration can be timed during the first year of life to provide protection from birth, or as early as possible. [1] In the recent HARMONIE trial findings, Beyfortus reduced RSV hospitalisations in infants by 82.7% (95% CI: 67.8 to 91.5; p<0,0001) through s
- 김갑성 기자
- 2025-11-24 16:55
Pin Therapeutics Initiates First-Patient Dosing of CK1α Degrad…

[ 메디채널 김갑성 기자 ] Preclinical Results Demonstrate Complete Response and Tumor Regression in ACC PDX Models SEOUL, South Korea, Nov. 24, 2025 -- Pin Therapeutics, a clinical-stage biotechnology company specializing in targeted protein degradation, announced on November 20 that it has administered the first dose of its CK1α-selective degrader PIN-5018 in a Phase 1 clinical trial. The first patient enrolled has adenoid cystic carcinoma (ACC), a rare malignancy with limited treatment options. PIN-5018 is an oral CK1α degrader developed based on the novel hypothesis of "
- 김갑성 기자
- 2025-11-24 15:11
Cigna Healthcare International Health Study Shows Physical…

More than half of Hongkongers (54%) rank physical health as their top well-being priority, compared to around one in three globally (35%) Weight management emerges as a key health focus, with 43% of Hongkongers prioritizing weight maintenance, well above the global average of 36%. Only 36% of the Hong Kong respondents aim to lose weight, the lowest in APAC Over seven in ten Hongkongers (77%) report experiencing stress, with 41% stressed about future uncertainty, 35% worried about personal finances, and 25% stressed about the cost of living Nearly half of the Hong Kong responde
- 김갑성 기자
- 2025-11-24 12:26
Chula Veterinarians Perform Thailand's First Pacemaker Impla…

BANGKOK, Nov. 24, 2025 -- In a groundbreaking medical milestone, veterinarians from Chulalongkorn University's Faculty of Veterinary Science have successfully performed Thailand's first pacemaker implantation in a cat, marking a new era in advanced veterinary cardiology. The procedure, led by Assoc. Prof. Dr. Anusak Kijtawornrat from the Department of Physiology, demonstrates Thailand's growing capacity in high-precision animal healthcare. The patient, Pepsi, an eight-year-old domestic shorthair cat, had suffered frequent fainting spells—up to four times daily—caused by severe
- 김갑성 기자
- 2025-11-24 12:00
쭐랄롱꼰 대학교 수의학팀, 태국 최초로 고양이 심박동기 삽입 수술 성공

[ 메디채널 김갑성 기자 ] 방콕, 2025년 11월 24일 -- 쭐랄롱꼰 대학교 수의학부 소속 수의사들이 태국 최초로 고양이 심박동기 삽입 수술을 성공적으로 시행했다. 이번 성과는 태국이 고도화된 수의 심장학 분야에서 새로운 단계로 진입했음을 보여주는 의학적 이정표다. 수술은 생리학과의 아누삭 키짜원랏(Anusak Kijtawornrat) 부교수가 이끌었다. 이번 성공으로 태국의 정밀 동물 의료 역량이 성장하고 있음을 입증했다. 환묘인 '펩시(Pepsi)'는 8세의 집고양이로, 심각한 부정맥으로 인해 하루 최대 네 차례 실신을 반복해 왔다. 심박동기 삽입 후 펩시는 완전히 회복했으며, 이후 평소의 활력과 식욕, 장난기 넘치는 성격을 되찾았다. 아누삭 부교수는 펩시의 상태가 심장 각 방 사이에서 전달되는 전기 신호가 차단돼 혈액이 뇌로 제대로 공급되지 못하는 문제에서 비롯됐다고 설명했다. 이러한 유형의 부정맥은 고양이에게 매우 드물며, 전체 고양이 심장병 사례 중 약 0.03%를 차지하고 주로 노령묘에서 발생한다. 펩시의 최종 진단은 표준 심전도(ECG) 검사보다 정확한 24시간 홀터 모니터링(Holter moni
- 김갑성 기자
- 2025-11-24 11:59

이전

21 22 23 24 25 26 27 28 29 30

많이 본 기사

최근기사

2025-12-10_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 12월 10일 21시 20분